CN1266129C - 具有降血脂和降低血中胆固醇活性的新化合物、其制备方法和含有它们的药物组合物 - Google Patents

具有降血脂和降低血中胆固醇活性的新化合物、其制备方法和含有它们的药物组合物 Download PDF

Info

Publication number
CN1266129C
CN1266129C CNB018068375A CN01806837A CN1266129C CN 1266129 C CN1266129 C CN 1266129C CN B018068375 A CNB018068375 A CN B018068375A CN 01806837 A CN01806837 A CN 01806837A CN 1266129 C CN1266129 C CN 1266129C
Authority
CN
China
Prior art keywords
phenyl
ethoxy
fluorophenyl
group
isopropyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB018068375A
Other languages
English (en)
Chinese (zh)
Other versions
CN1449381A (zh
Inventor
布拉杰·布尚·洛瑞
维迪亚·布尚·洛瑞
维贾伊·库马尔·加朱海·巴罗特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zydus Lifesciences Ltd
Original Assignee
Cadila Healthcare Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cadila Healthcare Ltd filed Critical Cadila Healthcare Ltd
Publication of CN1449381A publication Critical patent/CN1449381A/zh
Application granted granted Critical
Publication of CN1266129C publication Critical patent/CN1266129C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/325—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/325—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
    • C07D207/327—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/33—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/33—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/333—Radicals substituted by oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Reproductive Health (AREA)
  • Child & Adolescent Psychology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CNB018068375A 2000-01-19 2001-01-17 具有降血脂和降低血中胆固醇活性的新化合物、其制备方法和含有它们的药物组合物 Expired - Fee Related CN1266129C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN57/MUM/2000 2000-01-19
IN57MU2000 2000-01-19

Publications (2)

Publication Number Publication Date
CN1449381A CN1449381A (zh) 2003-10-15
CN1266129C true CN1266129C (zh) 2006-07-26

Family

ID=11097206

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB018068375A Expired - Fee Related CN1266129C (zh) 2000-01-19 2001-01-17 具有降血脂和降低血中胆固醇活性的新化合物、其制备方法和含有它们的药物组合物

Country Status (30)

Country Link
EP (1) EP1250323B1 (enExample)
JP (2) JP4213385B2 (enExample)
KR (1) KR100649304B1 (enExample)
CN (1) CN1266129C (enExample)
AP (1) AP1522A (enExample)
AU (1) AU779332B2 (enExample)
BG (1) BG65370B1 (enExample)
BR (1) BRPI0108024B8 (enExample)
CA (1) CA2397828C (enExample)
CZ (1) CZ304346B6 (enExample)
DK (1) DK1250323T3 (enExample)
DZ (1) DZ3279A1 (enExample)
EA (1) EA007959B1 (enExample)
EE (1) EE05082B1 (enExample)
ES (1) ES2449194T3 (enExample)
HR (1) HRP20020643B1 (enExample)
HU (1) HU230609B1 (enExample)
IL (2) IL150821A0 (enExample)
ME (1) MEP32408A (enExample)
MX (1) MXPA02007080A (enExample)
NO (1) NO324689B1 (enExample)
NZ (1) NZ520402A (enExample)
OA (1) OA12162A (enExample)
PL (1) PL222486B1 (enExample)
PT (1) PT1250323E (enExample)
SK (1) SK287294B6 (enExample)
UA (1) UA73546C2 (enExample)
WO (1) WO2001053257A2 (enExample)
YU (1) YU54902A (enExample)
ZA (1) ZA200205789B (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6440961B1 (en) 1997-10-27 2002-08-27 Dr. Reddy's Research Foundation Tricyclic compounds and their use in medicine: process for their preparation and pharmaceutical compositions containing them
US6369067B1 (en) 1997-10-27 2002-04-09 Dr. Reddy's Research Foundation Monocyclic compounds and their use in medicine: process for their preparation and pharmaceutical compositions containing them
US6130214A (en) 1997-10-27 2000-10-10 Dr. Reddy's Research Foundation Benzothiazin and benzoxazin derivatives; their preparation and uses
CA2307820C (en) 1997-10-27 2007-04-24 Dr. Reddy's Research Foundation Novel tricyclic compounds and their use in medicine; process for their preparation and pharmaceutical compositions containing them
HUP0101110A3 (en) 1997-10-27 2002-06-28 Reddys Lab Ltd Dr Bicyclic compounds, process for their preparation and pharmaceutical compositions containing them
US6531596B1 (en) 1998-10-29 2003-03-11 Dr. Reddy's Laboratories Ltd. Process for the preparation of new antidiabetic agents
IL142285A0 (en) 1998-10-29 2002-03-10 Reddy Research Foundation Process for preparing phenoxazine derivatives
US6897199B2 (en) 2001-02-05 2005-05-24 Dr. Reddy's Laboratories Ltd. Pharmaceutically acceptable salts of phenoxazine and phenothiazine compounds
US7220773B2 (en) 2001-04-19 2007-05-22 Dainippon Sumitomo Pharma Co., Ltd. Pyrrole derivative
US6987123B2 (en) 2001-07-26 2006-01-17 Cadila Healthcare Limited Heterocyclic compounds, their preparation, pharmaceutical compositions containing them and their use in medicine
EP1537099B1 (en) * 2002-08-23 2010-08-11 Novartis Vaccines and Diagnostics, Inc. Pyrrole based inhibitors of glycogen synthase kinase 3
DE10305089A1 (de) * 2003-02-07 2004-08-26 Merckle Gmbh Neue heteroarylsubstituierte Acetonderivate als Hemmstoffe der Phospholiphase A2
PL2670486T3 (pl) 2011-01-31 2016-08-31 Cadila Healthcare Ltd Leczenie lipodystrofii
JP5971657B2 (ja) * 2011-04-20 2016-08-17 塩野義製薬株式会社 Ｔｒｐｖ４阻害活性を有する芳香族複素環誘導体
GEP201706663B (en) 2013-04-22 2017-05-10 Cadila Healthcare Ltd Novel composition for nonalcoholic fatty liver disease (nafld
EP3004053B1 (en) 2013-05-30 2021-03-24 Cadila Healthcare Limited A process for preparation of pyrroles having hypolipidemic hypocholesteremic activities
TW201636015A (zh) 2013-07-05 2016-10-16 卡地拉保健有限公司 協同性組成物
IN2013MU02470A (enExample) 2013-07-25 2015-06-26 Cadila Healthcare Ltd
WO2015033357A2 (en) 2013-09-06 2015-03-12 Cadila Healthcare Limited An improved process for the preparation of pyrrole derivatives
US10385017B2 (en) 2015-10-14 2019-08-20 Cadila Healthcare Limited Pyrrole compound, compositions and process for preparation thereof
EP3551180B1 (en) 2016-12-09 2021-09-29 Cadila Healthcare Limited Treatment for primary biliary cholangitis
CN108191732B (zh) * 2018-02-23 2020-11-24 贝利化学（张家港）有限公司 一种n-甲基吡咯的合成方法
GB201905721D0 (en) 2019-04-24 2019-06-05 Univ Dundee Compounds

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DD86826A (enExample) *
US3534061A (en) * 1967-12-04 1970-10-13 Parke Davis & Co N-(alpha-(p-methoxyphenyl)-beta-nitrostyryl)-phenoxyalkyl pyrroles
DD88826B1 (de) * 1971-05-14 1973-11-20 Ljudmil Petkow Schaltungsanordnung zur Ansteuerung eines Wechselrichters für den definierten Antrieb eines Wechselstrommotors
US3980089A (en) * 1972-04-21 1976-09-14 International Flavors & Fragrances Inc. Novel heterocyclic flavoring compositions and processes
ZA781173B (en) * 1977-03-21 1979-02-28 Zoecon Corp Novel compositions
US4229352A (en) * 1979-08-13 1980-10-21 Zoecon Corporation Benzylpyrrolylmethyl esters of cyclopropane carboxylic acids
US4232038A (en) * 1979-08-31 1980-11-04 Syntex (U.S.A.) Inc. 5-Alkylsulfinylbenzoyl- and 5-alkylsulfonylbenzoyl-1,2-dihydro-3H-pyrrolo[1,]pyrrole-1-carboxylic acids
US4224330A (en) * 1979-09-13 1980-09-23 Zoecon Corporation Esters and thiolesters of benzothienyl acids
US4235777A (en) * 1979-11-19 1980-11-25 Zoecon Corporation Benzylpyrrolylmethyl esters of 3-(1,2-dibromo-2,2-dichloroethyl)-2,2-dimethylcyclopropanecarboxylic acid
US4410534A (en) * 1979-12-26 1983-10-18 Syntex (U.S.A.) Inc. 3-Substituted-5,6,7,8-tetrahydropyrrolo[1,2-a]-pyridine-and 6,7,8,9-tetrahydro-5H-pyrrolo[1,2-a]-azepine carboxylic acid derivatives useful as blood platelet aggregation inhibitors
US4344943A (en) * 1980-06-09 1982-08-17 Syntex (U.S.A.) Inc. 6-Chloro- or 6-bromo-1,2-dihydro-3H-pyrrolo[1,2-a]-pyrrole-1-carboxylic acids and derivatives thereof
US4560699A (en) * 1983-01-17 1985-12-24 Syntex (U.S.A.) Inc. 5-(4-Vinylbenzoyl)-1,2-dihydro-3H-pyrrolo-[1,2-a]-pyrrole-1-carboxylic acids and derivatives thereof and use as analgesics and anti-inflammatories
US4505920A (en) * 1983-03-03 1985-03-19 Usv Pharmaceutical Corporation Certain N-substituted-4-aryl-3,5-pyridine dicarboxylates and their antihypertensive use
DE3477662D1 (en) * 1983-06-17 1989-05-18 Ciba Geigy Ag 3-phenyl-4-cyanopyrrole derivatives, process for their preparation and their use as microbicides
US4546099A (en) * 1983-07-22 1985-10-08 Ciba-Geigy Corporation N-Aminomethyl-3-phenyl-4-cyanopyrrole derivatives, compositions and use thereof as microbicides
FR2563229B1 (fr) * 1984-04-20 1986-07-18 Commissariat Energie Atomique Materiau electrochrome organique, son procede de fabrication et son application a l'affichage
US5089514A (en) * 1990-06-14 1992-02-18 Pfizer Inc. 3-coxazolyl [phenyl, chromanyl or benzofuranyl]-2-hydroxypropionic acid derivatives and analogs as hypoglycemic agents
FR2674856B1 (fr) * 1991-04-05 1993-07-30 Esteve Labor Dr Nouveaux antihistaminiques non sedatifs, derives de benzimidazole, leur procede de preparation et leur utilisation en tant que medicaments.
EP0648212B1 (en) * 1992-07-03 2001-10-24 Smithkline Beecham Plc Benzoxazole and benzothiazole derivatives as pharmaceutical
IL107771A0 (en) * 1992-11-27 1994-02-27 Wellcome Found Pharmaceutical compositions containing isothiourea derivatives certain such novel compounds and their preparation
GB9225386D0 (en) * 1992-12-04 1993-01-27 Smithkline Beecham Plc Novel compounds
US5418242A (en) * 1993-05-18 1995-05-23 Laboratoires Upsa Piperidinylthioindole derivatives, their methods of preparation and pharmaceutical compositions in which they are present, useful especially as analgesics
US5387613A (en) * 1993-07-23 1995-02-07 Ribogene, Inc. Treatment of tachyarrhythmias of supraventricular origin
GB9326171D0 (en) * 1993-12-22 1994-02-23 Smithkline Beecham Plc Novel compounds
WO1996004261A1 (en) * 1994-07-29 1996-02-15 Smithkline Beecham Plc Benzoxazoles and pryridine derivatives useful in the treatment of the type ii diabetes
KR100380875B1 (ko) * 1995-04-28 2003-10-10 다이이찌 세이야꾸 가부시기가이샤 펜타사이클릭화합물
GB9600464D0 (en) * 1996-01-09 1996-03-13 Smithkline Beecham Plc Novel method
GB9606805D0 (en) * 1996-03-30 1996-06-05 Glaxo Wellcome Inc Medicaments
CZ298812B6 (cs) * 1996-07-01 2008-02-13 Dr. Reddy's Laboratories Limited Azolidindionové deriváty, způsob jejich přípravy, farmaceutické kompozice s jejich obsahem a jejich použití v léčbě diabetu a příbuzných nemocí
DE69723070T2 (de) * 1996-12-24 2005-02-17 Daewoo Motor Co., Ltd. Abgasrückführventil für brennkraftmaschine
ES2200248T3 (es) * 1997-09-19 2004-03-01 Ssp Co., Ltd. Derivados de acudi fenilpropionico sustituido en alfa y medicamento que los contienen.
WO1999019313A1 (en) * 1997-10-27 1999-04-22 Dr. Reddy's Research Foundation Novel tricyclic compounds and their use in medicine; process for their preparation and pharmaceutical compositions containing them
US6130214A (en) * 1997-10-27 2000-10-10 Dr. Reddy's Research Foundation Benzothiazin and benzoxazin derivatives; their preparation and uses
CA2307820C (en) * 1997-10-27 2007-04-24 Dr. Reddy's Research Foundation Novel tricyclic compounds and their use in medicine; process for their preparation and pharmaceutical compositions containing them
WO1999008501A2 (en) * 1998-04-23 1999-02-25 Dr. Reddy's Research Foundation New heterocyclic compounds and their use in medicine, process for their preparation and pharmaceutical compositions containing them
EP1082313A1 (en) * 1998-05-27 2001-03-14 Dr. Reddy's Research Foundation Bicyclic compounds, process for their preparation and pharmaceutical compositions containing them
US6747188B2 (en) * 1998-10-01 2004-06-08 North Carolina State University Transgenic plants expressing a mutant geminivirus AL3/C3 coding sequence
AU6325799A (en) * 1998-10-21 2000-05-08 Dr. Reddy's Research Foundation New compounds, their preparation and use

Also Published As

Publication number Publication date
PT1250323E (pt) 2014-04-07
CA2397828A1 (en) 2001-07-26
AP1522A (en) 2005-12-22
EA200200774A1 (ru) 2003-02-27
EA007959B1 (ru) 2007-02-27
HU230609B1 (hu) 2017-03-28
PL222486B1 (pl) 2016-08-31
PL365379A1 (en) 2005-01-10
AU779332B2 (en) 2005-01-20
CZ304346B6 (cs) 2014-03-19
KR100649304B1 (ko) 2006-11-24
MEP32408A (en) 2010-10-10
MXPA02007080A (es) 2003-09-25
SK10592002A3 (sk) 2003-03-04
HRP20020643B1 (hr) 2015-04-24
WO2001053257A3 (en) 2002-06-27
JP5144421B2 (ja) 2013-02-13
YU54902A (sh) 2005-06-10
UA73546C2 (en) 2005-08-15
BRPI0108024B1 (pt) 2015-09-15
BG65370B1 (bg) 2008-04-30
EE200200399A (et) 2003-10-15
OA12162A (en) 2006-05-08
IL150821A0 (en) 2003-02-12
NO20023400D0 (no) 2002-07-15
EP1250323B1 (en) 2014-01-01
NZ520402A (en) 2006-04-28
NO324689B1 (no) 2007-12-03
HUP0301811A3 (en) 2006-04-28
ES2449194T3 (es) 2014-03-18
JP4213385B2 (ja) 2009-01-21
SK287294B6 (sk) 2010-05-07
WO2001053257A2 (en) 2001-07-26
BR0108024A (pt) 2003-03-11
BG106932A (en) 2004-01-30
NO20023400L (no) 2002-09-09
EE05082B1 (et) 2008-10-15
CA2397828C (en) 2007-09-04
HK1058039A1 (en) 2004-04-30
AP2002002575A0 (en) 2002-09-30
AU4872801A (en) 2001-07-31
EP1250323A2 (en) 2002-10-23
KR20020075888A (ko) 2002-10-07
DZ3279A1 (fr) 2001-07-26
JP2003520268A (ja) 2003-07-02
JP2008308504A (ja) 2008-12-25
HRP20020643A2 (en) 2005-10-31
HUP0301811A2 (hu) 2003-09-29
BRPI0108024B8 (pt) 2021-05-25
IL150821A (en) 2008-12-29
DK1250323T3 (da) 2014-02-03
ZA200205789B (en) 2003-10-02
CN1449381A (zh) 2003-10-15

Similar Documents

Publication Publication Date Title
CN1266129C (zh) 具有降血脂和降低血中胆固醇活性的新化合物、其制备方法和含有它们的药物组合物
US6987123B2 (en) Heterocyclic compounds, their preparation, pharmaceutical compositions containing them and their use in medicine
CN1280575A (zh) 新型三环化合物和其作为药物的用途;其制备方法和包含该化合物的药物组合物
CN1352639A (zh) 新的三环化合物及其在医药中的应用,它们的制备方法和含有它们的药物组合物
CN1281443A (zh) 双环化合物、其制备方法和包含它们的药物组合物
JP2003520268A5 (enExample)
CN1774244A (zh) 用于治疗代谢紊乱的化合物
CN1780614A (zh) 用于治疗代谢紊乱的化合物
CN1617854A (zh) 苯基(烷基)羧酸衍生物和二酸苯基烷基杂环衍生物及其用作具有血清葡萄糖和/或血清脂降低活性的药物的应用
CN1777576A (zh) 用于治疗代谢紊乱的化合物
CN1930152A (zh) 用于治疗i.a.肥胖症和糖尿病的1,3－二噁烷衍生物及其类似物
CN1257893C (zh) 具有优异降糖降酯活性的芳烷基氨基酸类ppar全激活剂
CN1107843A (zh) 二氢化茚衍生物和其制法及合成该衍生物的中间体
CN1867546A (zh) 新颖化合物及其在药物中的用途、其制备方法以及含有它们的药物组合物
HK1058039B (en) Compounds having hypolipedemic and hypocholesteremic activities, process for their preparation and pharmaceutical compositions containing them
CN1863799A (zh) 治疗糖尿病和脂质紊乱的色原烷羧酸衍生物
CN1205205C (zh) 钠－氢交换剂1型抑制剂晶体
CN1738807A (zh) 取代的芳烷基衍生物
CN1894200A (zh) 用作抗高血糖剂的ω－取代的萘氧基氨基烷烃衍生物及其制备
CN1612875A (zh) 5－(4－(2－(n－甲基－n－(2－吡啶基)氨基)乙氧基)苄基)噻唑烷－2,4－二酮苯磺酸盐，它的制备方法，其多晶型物ⅰ、ⅱ、和ⅲ和它作为药物活性成分的用途
KR20060054270A (ko) 저지방혈증, 저콜레스테롤혈증 활성을 가지는 신규 화합물,그 제조방법 및 이를 포함하는 제약학적 조성물
CN1944383A (zh) α－烷氧丙酸类化合物及其制法和药物用途
CZ20001539A3 (cs) Nové tricyklické sloučeniny a jejich použití v medicíně, způsob jejich přípravy a farmaceutické kompozice s jejich obsahem
CN1795163A (zh) 羧酸化合物及含有该化合物的医药

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20060726

Termination date: 20180117